维普期刊资源整合服务平台（V6.5）

21篇 您的检索式：作者名="Rosner GL"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Phase Ⅰ evalution of prolonged - infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia 显示文摘	Rizzieri DA Bass AJ Rosner GL	2002	J Clin Oncol2002，20，3：	1
2	A phase I trial of es- calating doses of trastuzumab combined with daily subcutaneous interleukin 2:report of cancer and leukemia group B 9661 显示文摘	Fleming GF Meropol NJ Rosner GL	2002	Clin Cancer Res2002，8，12：	1
3	Phase Ⅰ and pharmacokinetics trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565显示文摘	Egorin MJ Rosner GL	2000	J Clin Oncol2000，18，14：	1
4	Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models显示文摘	Rosner GL Müller P	1997	J Pharmacokinet Biopharm1997，25，：	1
5	Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodyamics in women with solid tumors显示文摘	Miller AA Rosner GL Egorin MJ	2004	Clin Cancer Res2004，10，24：	1
6	Bayesian inference for the leadtime in periodic Cancer screening显示文摘	Wu D Rosner GL Broerneling LD	2007	Biometrics2007，63，3：	1
7	PhaseⅠevaluation ofprolonged-infusion gemcitabine with mitoxantrone for relapsed orrefractory acute leukemia显示文摘	Rizzieri DA Bass AJ Rosner GL	2002	J Clin Oncol2002，20，3：	1
8	MGMT promoter methylation and field defect in sporadic colorectal cancer显示文摘	Shen L Kondo Y Rosner GL	2005	J Natl Cancer In- st2005，97，18：	1
9	Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models显示文摘	Rosner GL Muller P	1997	J Pharmacokinet Biopharm1997，25，2：	1
10	MGMT promoter methylamine and field defect in sporadic eolorectal cancer 显示文摘	Shen L Kondo Y Rosner GL	2005	J Nall Cancer Ins12005，97，18：	1
11	Using units of CEM 43℃ T90 local hyperthermia thermal dose can be delivered as prescribed显示文摘	Thrall DE Rosner GL Azuma C	2000	International Journal of Hyperthermia2000，16，5：	1
12	MGMT promoter methylation and field defect in sporadic colorectal cancer显示文摘	Shen L Kondo Y Rosner GL		0，，18：	1
13	Randomized discontinuation design:application to cytostaticantineoplastic agents 显示文摘	Rosner GL Stadler W Ratain MJ	2002	J ClinOncol2002，20，22：	1
14	Bayesian in ference for the lead time in periodic cancer screening显示文摘	Wu D Rosner GL Broemeling LD	2007	Biometries2007，63，3：	1
15	Methotrexate pharmacokinetics in infants with acute lymphoblastie leuke-mia显示文摘	Thompson PA Murry D J Rosner GL	2007	Cancer Chemother Pharrnaeol2007，59，6：	1
16	Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma显示文摘	Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Desai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B O'Dwyer PJ	2006	J Clin Oncol2006，24，16：	1
17	A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871 显示文摘	Lewis LD Miller AA Rosner GL	2007	Clin Cancer Res2007，13，11：	1
18	MGMT promoter methylatian and field defect in sporadic colorectal cancer显示文摘	Shen L Kondo Y Rosner GL	2005	J Natl Cancer Inst2005，97，：	1
19	Bayesian inference for the lead time in periodic cancer screening显示文摘	Wu D Rosner GL Broemeling LD	2007	Biometrics2007，63，3：	1
20	Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group显示文摘	Thompson PA Gupta M Rosner Gl	2008	Cancer Chemother Pharmacol2008，62，6：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示